OUR VISION
We believe our work at SYNSIGHT goes towards exploiting the tools of modern biology to generate qualitative data sets rather than relying on existing but unreliable data.
OUR PIPELINE
The company develops a screening technology that enables the development of effective First in Class drug candidates based on a discovery platform to the convergence of artificial intelligence and cell imaging.
OUR APPROACH
We developed a platform that benefits from new technologies that have been widely developed in recent years : AI, cellular imaging, robotization.
The convergence of these technologies and the close collaboration of data scientists and biologists make it possible to create biological models of very large size and significance
GET IN TOUCH
We will get back to you as soon as possible
@SYNSIGHT2021. ALL RIGHTS RESERVED.
Genopole Entreprises
4 rue Pierre Fontaine
91058 EVRY
FRANCE
